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ABSTRACT
The role of HER4 in breast cancer is controversial and its role in relation to 
trastuzumab resistance remains unclear. We showed that trastuzumab treatment and 
its acquired resistance induced HER4 upregulation, cleavage and nuclear translocation. 
However, knockdown of HER4 by specific siRNAs increased trastuzumab sensitivity 
and reversed its resistance in HER2 positive breast cancer cells. Preventing HER4 
cleavage by a γ-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by 
neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced 
trastuzumab response. There was also increased nuclear HER4 staining in the 
tumours from BT474 xenograft mice and human patients treated with trastuzumab. 
Furthermore, nuclear HER4 predicted poor clinical response to trastuzumab 
monotherapy in patients undergoing a window study and was shown to be an 
independent poor prognostic factor in HER2 positive breast cancer. Our data suggest 
that HER4 plays a key role in relation to trastuzumab resistance in HER2 positive 
breast cancer. Therefore, our study provides novel findings that HER4 activation, 
cleavage and nuclear translocation influence trastuzumab sensitivity and resistance 
in HER2 positive breast cancer. Nuclear HER4 could be a potential prognostic and 
predictive biomarker and understanding the role of HER4 may provide strategies to 
overcome trastuzumab resistance in HER2 positive breast cancer.
INTRODUCTION
HER4 is a cell surface receptor that belongs to the 
human epidermal growth factor receptor (HER/ErbB) 
family [1, 2]. The signaling by HER4 is initiated through 
ligand binding of heparin-binding EGF, betacellulin 
and epiregulin (co-ligands with EGFR/HER1) [3, 4] 
or heregulin (NRG1-4) [3, 5, 6]. HER4 activation by 
its different ligands results in variable combination 
of HER4 as dimers and transphosphorylation on its 
tyrosine residues, as well as the initiation of a cascade of 
downstream signaling pathways [3-7]. 
The role of HER4 in breast cancer remains 
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controversial. In many studies, HER4 has been identified 
to have an anti-proliferative activity, which is contrary to 
other HER family members [8-10]. In addition, positive 
HER4 expression was shown to be associated with an 
increased survival rate of breast cancer patients [11]. A 
recent study conducted among HER2 positive breast 
cancer patients demonstrated that HER4 is predictive 
of longer event-free survival (EFS) in patients with ER 
positive tumours [12]. That study is in agreement with 
previous reports that linked high HER4 expression with 
low tumour grade, low proliferation rate and positive 
score for ER and PR in breast cancer [13-15]. However, 
there are also some studies correlated HER4 with 
increased cellular growth and oncogenic properties [16-
18]. Bieche [19] reported that breast cancer patients with 
tumours overexpressing HER4 had a shorter survival rate, 
suggesting HER4 maybe an important biomarker for poor 
prognosis. 
The role of HER4 in relation to trastuzumab 
treatment and resistance remains unclear. Although HER4 
expression has been shown to improve trastuzumab 
response [20, 21], there has been no detailed report on 
how trastuzumab affects HER4 expression, activation 
and cleavage and how these processes mediate sensitivity 
and resistance to trastuzumab in HER2 positive breast 
cancer cells. The aim of this study is to elucidate the 
role and prognostic significance of HER4 expression 
and localisation in relation to trastuzumab treatment and 
resistance in HER2 positive breast cancer. 
RESULTS
Trastuzumab treatment and exogenous heregulin 
stimulation induce the upregulation of HER4180kDa 
and HER480kDa in HER2 positive breast cancer
We have previously reported that gefitinib and 
trastuzumab induce the endogenous release of heregulin 
in HER2 amplified breast cancer cells [22, 23]. In this 
study, we compared the effect of trastuzumab to exogenous 
heregulin stimulation on HER4 expression and activation 
in HER2 amplified SKBR3 and BT474 cells. MCF7 cells 
were used as the control cell line since they have a low 
level of HER2. The basal expression of HER4 in SKBR3 
was comparable to the expression in MCF7, although it 
was lower in BT474 cells (Supplementary Figure 1A). 
Using two different antibodies of HER4 cytoplasmic 
domain, we showed that exogenous heregulin stimulation 
increased HER4 protein; and the mRNA levels were 
concordantly upregulated (Figure 1A-C). Similarly, 
exogenous heregulin stimulation or one-hour trastuzumab 
treatment resulted in an upregulation of HER4180kDa 
and HER480kDa forms as well as an increase of HER4 
phosphorylation in SKBR3 cells (Figure 1B). Using 
the Neomarkers’ antibody to the cytoplasmic domain 
of HER4, western blots showed that there was also 
an increase of HER4 bands at 110 kDa and 120kDa in 
BT474 cells, which were not clearly seen in SKBR3 
cells (Figure 1C). However, these two additional bands 
could be visualised using another anti-HER4 antibody 
from Santa Cruz. The immunoblot using these two 
different HER4 antibodies showed that the bands around 
180 kDa, 110 kDa, 120 kDa and 80kDa (also known as 
m80) decreased following HER4 silencing, indicating 
that these are specific HER4 bands (Figure 3B). In HER2 
negative MCF7 cells, trastuzumab treatment and heregulin 
stimulation also induced an upregulation of HER4 at 
180kDa but no obvious increase in HER480kDa was detected 
(Supplementary Figure 1B). Since one-hour trastuzumab 
treatment upregulated HER4 expression, we next 
determined the dose effect of trastuzumab on HER4 at 
this time point. There was a dose responsive upregulation 
of HER480kDa from 10 to 20 µg/ml trastuzumab in SKBR3 
and BT474 cells but no further increase beyond 20 µg/ml 
dose was seen (Supplementary Figure 1C). No obvious 
changes in HER2 level could be detected with increasing 
doses of trastuzumab treatment in SKBR3 and BT474 
cells after 1 hour. 
HER4180kDa and HER480kDa increase upon acquired 
resistance to trastuzumab
We also performed a time-course experiment to 
assess the effect of trastuzumab treatment on HER4 
expression in SKBR3 and BT474 cells in comparison 
with the acquired resistant cells generated in the lab [23] 
(Supplementary Figure 1D). In the parental SKBR3 cells, 
trastuzumab treatment significantly increased HER4180kDa 
and HER480kDa after a 24-hour treatment (n=3, p<0.01) 
and also in acquired resistant SKBR3 cells (n=3, p<0.001) 
(Figure 1D, left panel). Similar results were seen in the 
parental and resistant BT474 cells (Figure 1D, right 
panel). In contrast to trastuzumab-resistant cells that 
were continuously treated with trastuzumab, an overnight 
trastuzumab withdrawal reduced HER4180kDa and HER480kDa 
significantly (n=3, p<0.001) in the trastuzumab-resistant 
SKBR3 cells but not in the resistant BT474 cells (Figure 
1D). There was also a statistically significant increase 
of HER4 mRNA levels after trastuzumab treatment and 
upon acquired resistance (Figure 1E). Withdrawal of 
trastuzumab from the resistant SKBR3 cells decreased 
HER4 mRNA level (n=3, p<0.001) (Figure 1E, left 
panel), which was not seen in BT474 cells (Figure 1E, 
right panel). 
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Heregulin stimulation and trastuzumab treatment 
induce HER4 nuclear translocation 
We next assessed the effect of heregulin stimulation 
and trastuzumab treatment on HER4 localisation. In 
untreated parental SKBR3 cells, HER4 was localized 
to both cytoplasmic and nuclear compartments (Figure 
2A). Heregulin stimulation (Supplementary Figure 2A) 
and trastuzumab treatment (Figure 2A) induced HER4 
nuclear localisation in SKBR3 cells. Compared to the 
untreated SKBR3 cells, the percentage of the cells that 
had nuclear HER4 staining was increased at 24 hours 
after trastuzumab treatment (n=3, p<0.001) (Figure 
2A, right panel). There was also increased basal HER4 
nuclear translocation in acquired resistant SKBR3 cells 
(n=3, p<0.001) (Figure 2A, right panel) and resistant 
BT474 cells (n=3, p<0.05) (Supplementary Figure 2B). 
Trastuzumab withdrawal in trastuzumab resistant SKBR3 
cells significantly decreased the percentage of positive 
nuclear HER4 cells (n=3, p<0.01) (Figure 2A, right panel). 
Cell fractional experiments showed that trastuzumab 
treatment upregulated HER4180kDa but not HER480kDa in 
the cytoplasmic fraction (Figure 2B). However, there was 
an increased HER480kDa in the nuclear fraction, correlated 
with the HER4 localisation seen in confocal experiments 
(Figure 2B). 
We also investigated an in vivo BT474 xenograft 
model. We first optimized HER4 immunohistochemistry 
Figure 1: HER4 expression is upregulated following heregulin stimulation and trastuzumab treatment. (A) The left panel 
shows the western blot of HER4 after 100ng/ml heregulin stimulation at different time points in SKBR3 cells. Right, SKBR3 cells were 
stimulated with 100ng/ml heregulin and HER4 expression was assessed by RT-PCR. HER4 mRNA of each group was quantified relative 
to the untreated cells, and normalised to β-actin. (B & C) SKBR3 and BT474 cells were treated with 40μg/ml trastuzumab or stimulated 
with 100ng/ml heregulin for one-hour before western blot analysis for the indicated proteins. Two different anti-HER4 antibodies, HER4 
(Neomarkers) and HER4 C18 (Santa Cruz: SC283) were used. The quantification of HER4 protein level was done for anti-HER4 antibody 
from Neomarkers after normalised to β-actin (bottom panels). Means ± SD from three independent experiments are shown in the graph 
(*p<0.05, **p<0.01, ***p<0.001). (D) The figures show the representative western blots (upper panels) of HER4 and their quantification 
(lower panels) from sensitive SKBR3 and BT474 cells treated with 40µg/ml trastuzumab at 0, 1, 4 and 24 hours in comparison with 
trastuzumab-resistant cells (with or without trastuzumab 24 hr withdrawal). The resistant cell lines were previously generated by a 
continuous treatment with 40µg/ml trastuzumab for more than 8 months [23]. (E) HER4 mRNA levels of sensitive and trastuzumab 
resistant SKBR3 and BT474 cells were measured. β-actin mRNA was used for normalization and the quantification was relative to the 
untreated cells. The means of HER4 mRNA ± SD from three independent experiments are shown in the graph (**p<0.01, ***p<0.001). 
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(IHC) staining using a HER2 positive cell pellet 
(Supplementary Figure 2C). Figure 2C (left panels) 
shows an example each of HER4 IHC staining on BT474 
xenograft tumour samples treated with either control or 
trastuzumab [24]. In the untreated group, HER4 cytoplasm 
was stained homogenously with no or minimal HER4 
staining in the nucleus. Following trastuzumab treatment 
for two and half weeks, HER4 was increased at both 
cytoplasm and nucleus but only nuclear HER4 staining 
was statistically significant (median IRS score=3, n=3) 
compared to the control (median IRS score=0, n=5) 
(p<0.05) (Figure 2C, right panel). Taken together, the 
data shows that trastuzumab treatment and resistance 
induced HER4 nuclear translocation in vitro; and there 
was increased cytoplasmic and nuclear HER4 staining in 
BT474 xenograft models treated with trastuzumab.
HER4 knockdown decreases cell viability and 
enhances trastuzumab response
To further understand the role of HER4 in 
trastuzumab-treated HER2 positive breast cancer cell 
lines, we performed HER4 knockdown by transient 
transfection with specific HER4 siRNAs, with or without 
trastuzumab treatment. Two independent HER4 siRNAS, 
HER4 siRNA10 and HER4 siRNA11 diminished HER4 
mRNA and protein expression significantly in SKBR3 
cells and BT474 cells (Figure 3A and 3B). The addition 
of trastuzumab increased HER4 mRNA and protein levels 
in the control siRNA treated cells (Figure 3A and 3B). 
Figure 2: Nuclear HER4 localisation is induced in vitro and in vivo after trastuzumab treatment. (A) Left, representative 
confocal images from sensitive and acquired resistant SKBR3 cells treated with 40μg/ml trastuzumab are shown. Right, a graph shows the 
percentage of positive cells stained with HER4-Alexa Fluor 546 at cytoplasmic and nuclear localisation. Means ± SD from three independent 
experiments are shown in the graph. 1-way ANOVA test with Bonferroni’s multiple comparisons was applied to determined significant 
differences between the groups (**p<0.01, ***P<0.001).   (B) Western blot analysis was performed on the cytoplasmic and nuclear 
fractions of SKBR3 cells isolated using NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo Scientific). After cell fractionation, 
GAPDH and Histone-3 levels were used as the loading control for cytoplasm fraction and nuclear fraction respectively. (C) Left, HER4 
staining by IHC in untreated and trastuzumab treated BT474 xenografts. The xenografts consist of mice treated with either trastuzumab 
or control for two weeks [24]. HER4 expression was scored semiquantitatively using the immunoreactive score (IRS) as described in 
the methods. Right, the cytoplasmic and nuclear HER4 scorings of trastuzumab-treated and the control groups are presented in a graph. 
Mann-Whitney test was used to determine the difference in median IRS scores between the untreated and trastuzumab-treated group. The 
statistical significance was denoted as * p<0.05.
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Although HER4 silencing could not completely prevent 
trastuzumab-induced increase in the mRNA and protein 
levels of HER4, they were less than the control siRNA 
treated cells (Figure 3A and B). HER4 knockdown 
also lead to a decrease of HER4 phosphorylation in 
trastuzumab treated and untreated cells (Figure 3B). 
Although HER4 knockdown had no effect on HER2 
level, there was a decrease in pHER2 level, indicating the 
dependency of HER2 activation on HER4. 
We proceeded to assess the effect of HER4 
knockdown with or without trastuzumab treatment using 
cell viability experiments in SKBR3 and BT474 (Figure 
3C). Although HER4 knockdown alone has a minimal 
effect in decreasing the cell number and apoptosis in 
both cell lines, it had an inhibitory effect on tumour 
colony formation in SKBR3 cells (and not in BT474 
cells) (Figure 3C-E). However, HER4 knockdown 
enhanced trastuzumab sensitivity significantly as shown 
by decreasing cell number and colony formation as well 
as increasing apoptosis in both SKBR3 and BT474 cells 
compared to the control cells (Figure 3C-E). 
To further assess the role of HER4 in acquired 
resistance to trastzumab, HER4 was also silenced in 
trastuzumab resistant cells in the presence or absence 
of continuous trastuzumab treatment. Trastuzumab 
withdrawal decreased HER4 m80 and pHER4 in the 
resistant SKBR3 cells but not in the resistant BT474 
cells (Figure 4A and 4B). HER4 and its phosphorylation 
also decreased after HER4 knockdown with and without 
combination treatment with trastuzumab (Figure 4A and 
Figure 3: HER4 silencing decreases cell viability and enhances trastuzumab responses. (A) SKBR3 and BT474 cells were 
transfected with HER4 siRNA10 and siRNA11, with and without 40μg/ml trastuzumab treatment before the mRNA levels were measured 
by RT-PCR. The scr (scramble) siRNA was used to normalize for transfection efficiency. Expression of HER4 is relative to the untreated 
scramble control and is normalised to β-actin. (B) Representative western blots of the indicated proteins from HER4 siRNA experiments 
in (A) are shown. (C) Cell count experiments were performed in SKBR3 and BT474 cells after 72-hour transfection as in (A) and the 
relative cell counts (normalized to the scr control) is shown in the graph. Means ± SD of three independent experiments is shown (**p<0.01 
***p<0.001). (D) The effect of HER4 siRNAs in SKBR3 and BT474 cells was further investigated in colony formation experiments after 7 
days post transfection as in (A). Representative colony pictures are shown on the upper panels and the relative colony counts (means ± SD) 
are shown on the bottom panels. (E) SKBR3 and BT474 cells transfected with transient HER4 siRNA (with and without trastuzumab) for 72 
hours were stained for Annexin V and the percentage of positive cells was assessed by FACS analysis. Means ± SD from three independent 
experiments are shown in the graph (*p<0.05, ***p<0.001). 
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Figure 4: HER4 silencing reverses trastuzumab resistance and decreases cell counts in trastuzumab-resistant cells. (A 
& B) Trastuzumab-resistant SKBR3 and BT474 cells were transfected with HER4 siRNA10 and siRNA11 in the presence (C) or withdrawal 
(W) of trastuzumab before western blot analysis for the indicated proteins.The middle and right panels show a relative quantification 
of HER4 and pHER4 levels from 3 independent experiments using Image J software. A 1-way ANOVA test with Bonferroni’s multiple 
comparison was applied to determine significant differences between the groups (n.s=not significant, *p<0.05, ***p<0.001) (C & D) Cell 
count experiments were performed at 72 hr post transfection after siRNA experiments as in (A) and (B). The graphs show relative cell 
count relative to the scramble resistant cells. The mean ratios of cell counts ± SD from three independent experiments are shown (**p<0.01, 
***p<0.001).
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4B). Although total HER2 level remained unchanged, 
pHER2 level increased when trastuzumab was withdrawn 
from trastuzumab-resistant cells transfected with either the 
control or HER4 siRNAs (Figure 4A and 4B). 
HER4 knockdown had an inhibitory effect on the 
cell count and reversed trastuzumab resistance in both 
resistant cell lines continuously treated with trastuzumab 
(Figure 4C and 4D). However, trastuzumab withdrawal 
diminished the inhibitory effect of HER4 knockdown in 
the resistant cells (Figure 4C and 4D). 
γ-secretase inhibitor decreases HER4 cleavage 
and nuclear translocation as well as enhancing 
trastuzumab sensitivity
Gamma-secretase (γ-secretase) is involved in the 
proteolytic cleavage of transmembrane HER4 following 
the initial release of extracellular domain by ADAM17, 
resulting in the production of cleaved HER480kDa and its 
nuclear translocation [25, 26]. Since we have shown that 
trastuzumab increased HER480kDa and induced its nuclear 
translocation in HER2 positive breast cancer (Figure 2A 
and 2B), we tested whether a γ-secretase inhibitor (GSi) 
could prevent HER4 nuclear localisation induced by 
trastuzumab treatment. Although trastuzumab treatment 
increased HER480kDa (Figure 5A), the combination 
treatment of trastuzumab with GSi in SKBR3 prevented 
the increase. Figure 5B (left panel) shows the confocal 
images from SKBR3 treated with GSi, in the presence or 
absence of trastuzumab treatment for 24 hour. GSi alone 
decreased HER4 intensity in the nucleus compared to the 
control (n=3, p<0.001) (Figure 5B). In addition, Figure 
5B also shows that when GSi was added to trastuzumab, 
not only did it decrease trastuzumab induced nuclear 
HER4 enhancement, but there was also an upregulation 
of cytoplasmic HER4 intensity. The decreased of the 
percentage of positive nuclear HER4 staining in the 
Figure 5: Gamma-secretase inhibitor prevents nuclear translocation and reverses resistance in trastuzumab-resistant 
cells. (A & B) SKBR3 cells were treated with 10µM γ-secretase inhibitor (GSi) with or without 40μg/ml trastuzumab before performing 
western blot analysis and confocal microscopy to investigate HER4 expression by IHC and localization by confocal microscopy. (C) 
Cell count and apoptosis assays were performed after treatments as in (A) and (B). Means ± SD from three independent experiments are 
shown (***p<0.001). (D) Figures show the representative HER4 immunoblots on cytoplasmic and nuclear fractions from trastuzumab-
resistant SKBR3 cells treated with GSi.  (E) The effect of GSi on trastuzumab-resistant SKBR3 was studied using colony formation assay. 
Representative colony pictures are shown on the upper panel and the relative ratio of colony counts are shown on the bottom panel. 
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combination treatment of GSi and trastuzumab was 
statistically significant compared to trastuzumab alone 
or trastuzumab with DMSO (n=3, p<0.001) (Figure 5B, 
right panel). After 3 days of treatment, trastuzumab in 
combination with GSi resulted in a significant decrease 
in cell viability of SKBR3 cells compared to trastuzumab 
alone or GSI alone (Figure 5C, upper panel). There were 
also a significant increase in the number of apoptotic 
SKBR3 cells, when treated with the combination of GSi 
and trastuzumab, as compared to trastuzumab alone or GSi 
alone (Figure 5C, bottom panel). In trastuzumab-resistant 
SKBR3 cells continuously treated with trastuzumab, 
GSi decreased HER480kDa in the nucleus (Figure 5D). 
Trastuzumab withdrawal resulted in a decrease in the 
nuclear HER480 but GSi did not further change its level 
in resistant SKBR3 cells. Trastuzumab withdrawal in 
the trastuzumab-resistant SKBR3 cells did not show any 
significant effect on colony formation. However, GSi 
decreased colony formation in resistant cells with or 
without trastuzumab treatment (Figure 5E). 
Neratinib prevented trastuzumab-induced 
upregulation of HER4 in the cytoplasm and the 
nucleus
Neratinib is an irreversible TKI targeting tyrosine 
kinase activities of HER1, HER2 and HER4 [27]. We have 
previously reported that neratinib enhances trastuzumab 
response and is effective in overcoming the acquired 
resistance of trastuzumab [28]. However, its effect on 
HER4 cleavage and localisation was not investigated. 
Since HER4 cleavage is induced upon its activation [3-7], 
we proceeded to assess the effect of neratinib on HER4 
deactivation as well as its expression and localisation in 
HER2 positive breast cancer cells. As expected, neratinib 
decreased HER4 tyrosine kinase phosphorylation in 
SKBR3 cells (Figure 6A). Neratinib treatment (in the 
presence or absence of trastuzumab) led to a decrease in 
both 180 kDa and 80 kDa of HER4 in the total cell lysate 
of SKBR3 cells (Figure 6A). In the parental and resistant 
BT474 cells, neratinib also decreased the intensity of 
several HER4 bands around 180kDa, 110kDa and 80kDa 
with and without trastuzumab in the total cell lysate 
(Supplementary Figure 3A). 
We also performed cell fractionation experiments 
and showed that neratinib prevented trastuzumab-
induced increase of HER480kDa in the nucleus after 24h 
neratinib treatment in SKBR3 cells. However, neratinib 
alone did not decrease m80 in the nucleus (Figure 6B). 
Confocal images also showed that there was a decrease 
in the percentage of cells with positive HER4 staining 
in the sensitive and resistant SKBR3 cells treated with 
a combination treatment of trastuzumab and neratinib, 
as compared to trastuzumab treatment alone (both n=3, 
p<0.001) (Figure 6C). These results correlated with a 
greater inhibitory effect of the combination treatment of 
neratinib with trastuzumab compared to trastuzumab alone 
on colony formation in both sensitive and resistant SKBR3 
cells (Supplementary Figure 3B).
In BT474 xenograft models treated with 
trastuzumab and/or neratinib [28], there was an increase 
in cytoplasmic and nuclear HER4 staining in xenograft 
tumour samples treated with trastuzumab. There was no 
difference in the nuclear and cytoplasmic HER4 scorings 
between those treated with neratinib and the control. 
However, trastuzumab-induced HER4 upregulation was 
prevented by the combination treatment of trastuzumab 
with neratinib (Figure 6D). The decrease in nuclear HER4 
scoring was statistically significant in the combination 
treatment of trastuzumab and neratinib (median IRS 
score=0, n=5) compared to trastuzumab alone (median 
IRS score=6, n=5) (p<0.05) (Figure 6D, right panel). 
Nuclear HER4 is a prognostic factor in HER2 
positive breast cancer patients
To assess the prognostic value of HER4 localisation, 
we stained TMAs from a well-annotated cohort of HER2 
positive breast cancer patients for HER4 expression. The 
characteristics of the patients and tumour parameters are 
listed in Supplementary Table 1. The results showed that 
high cytoplasmic HER4 was significantly correlated with 
better overall survival (OS) and relapse-free survival 
(RFS) than that of patients with low cytoplasmic HER4 
(OS: HR = 0.19, 95% CI = 0.04-0.80, p = 0.024; RFS: 
HR = 0.27, 95% CI = 0.09-0.85, p = 0.026) (Figure 7A). 
In contrast, Kaplan-meier analysis of nuclear HER4 
expression demonstrated an inverse correlation between 
positive nuclear HER4 expression and patient survival 
(IRS score ≥ 1 vs IRS score = 0; OS: HR = 13.63, 95%CI 
= 2.88-64.53, p < 0.001; RFS: HR = 6.08, 95%CI = 1.78-
20.81, p = 0.004) (Figure 7B). In a multivariate analysis 
with nuclear HER4-derived groups adjusted for ER and 
nodal status, nuclear HER4 remained an independent 
prognostic factor for OS (p = 0.002) and RFS (p = 0.011); 
whereas cytoplasmic HER4 appeared to be a weak 
prognostic predictor of OS (p = 0.059) and RFS (p = 
0.058) (Supplementary Table 2). 
Nuclear HER4 is predictive of trastuzumab 
response in HER2 positive breast cancer patients
We also assessed HER4 expression in HER2 
positive breast cancer patients who received trastuzumab 
monotherapy followed by neoadjuvant chemotherapy 
with trastuzumab treatment (Figure 7C). The patient 
characteristics and tumour parameters are listed 
in Supplementary Table 3. There were 5 out of 10 
patients underwent biopsy before and after trastuzumab 
monotherapy treatment. After trastuzumab monotherapy, 
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Figure 6: Neratinib prevents nuclear HER4 translocation induced by trastuzumab in vitro and in vivo. (A) SKBR3 cells 
were treated with 100 nM neratinib or/and 40μg/ml trastuzumab for 24 hours before western blot analysis for the indicated proteins. (B) 
Western blot analysis was performed on the cytoplasmic and nuclear fractions of SKBR3 cells after treatments in (A). On the left panels, 
the representative blots are shown.  The right panels show a relative quantification of HER4 and pHER4 from 2 independent experiments 
using Image J software. Although multiple independent experiments were done, only two experiments provided adequate quality of HER4 
immunoblot for quantification. (C) Sensitive and resistant SKBR3 cells were treated with 100 nM neratinib and/or 40μg/ml trastuzumab 
before being fixed for confocal microscopy. Representative confocal images from different treatment conditions are shown on the upper 
panel. The right panel shows the percentage of positive cells stained with HER4-Alexa Fluor 546 at nuclear localisation. Means ± SD 
from three independent experiments are shown in the graph. 1-way ANOVA test with Bonferroni’s multiple comparisons was applied to 
determined significant differences between the groups (*p<0.05, ***p<0.001).(D) BT474 xenografts were treated with vehicle control, 
neratinib, trastuzumab or their combination [28] and the tumour slides were stained for HER4 expression using IHC. Representative tumour 
sections from formalin-fixed, paraffin embedded tumour tissues of animals receiving different treatments are shown in the left panels. The 
IRS scores of HER4 immunohistochemical staining of cytoplasmic and nuclear localisation of the tumours are shown in the right panels. 
Kruskal-Wallis with Dunn’s multiple comparisons test was used to determine the difference in median IRS scores between the treatment 
groups (*P<0.05).
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there was a statistically significant upregulation of nuclear 
HER4 expression in the tumour biopsies collected at day 
21 compared to the biopsies from the initial diagnosis 
(mean HER4 IRS at day 21=3.20, 95%CI = 1.84-4.56 vs. 
mean HER4 IRS at baseline=0.80, 95%CI=-0.56-2.16, 
p=0.025) (Figure 7D). In addition, higher nuclear HER4 
expression at day 21 was correlated with a poorer clinical 
response to trastuzumab monotherapy, including a higher 
tumour volume (r=0.859, p=0.023) and Ki67 level ratios 
(r=0.897, p=0.014) (Figure 7E). However, there was no 
statistically significant difference in the tumour nuclear 
HER4 expression between baseline and after neoadjuvant 
chemo with trastuzumab (Supplementary Figure 4A). In 
addition, nuclear HER4 after neoadjuvant chemotherapy 
did not correlate with the tumour volumes and Ki67 values 
obtained from definitive surgery (Supplementary Figure 
4B).
DISCUSSION
In this study, we showed that trastuzumab treatment 
upregulated HER4 at 180 kDa and 80 kDa in SKBR3 and 
BT474 cells, the common HER4 variants reported from 
the previous study [29, 30]. HER480kDa has been described 
as a cleaved fragment of HER4 and is known to translocate 
to the nucleus [8, 31-33]. Our study demonstrates 
that trastuzumab-induced HER480kDa correlated with 
increased HER4 nuclear intensity from confocal images 
Figure 7: Nuclear HER4 predicts poorer trastuzumab response and is an adverse prognostic marker in HER2 positive 
breast cancer patients. (A & B) TMAs containing paraffin embedded breast tumours from a well-annotated HER2 positive breast cancer 
patients were stained for HER4 expression by IHC. Patients were split into two groups according to the positive and negative cytoplasmic 
and nuclear HER4 staining as defined in the methods section. The relapse-free survival and overall survival of the two groups were plotted 
in Kaplan-Meier curves according to the cytoplasmic and nuclear HER4 staining in breast cancer patients (n=73). (C) A schematic diagram 
shows a window of opportunity study conducted among HER2 positive breast cancer patients who received trastuzumab monotherapy 
followed by neoadjuvant chemotherapy with trastuzumab before surgery. Tumour specimens were collected at the baseline, 21 days after 
trastuzumab monotherapy and at the final stage after completed 4 cycles of neoadjuvant docetaxel chemotherapy 100 mg/m2 with 6mg/kg 
trastuzumab. (D) Nuclear HER4 expression was analysed using IHC in paired tissue samples (baseline and at 21 days) from 5 patients who 
received one dose of trastuzumab monotherapy. The differences in HER4 IRS scores between the pairs were asssesed by paired t-test (* 
indicates p<0.05). (E) Nuclear HER4 expression at day 21 was correlated with the ratios of tumour volumes and Ki67 stainings (between 
day 21 and baseline) using linear regression (upper panels). The table below shows the HER4 scorings of the individual 5 patients with their 
respective tumour volume and Ki67 ratios.
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and increased cleaved HER4 fragment (HER480kDa) in 
the nuclear fraction of trastuzumab treated cells. The 
xenograft experiments also showed that nuclear HER4 
staining was significantly increased in the tumours of the 
mice treated with trastuzumab compared to the untreated 
group. Furthermore, trastuzumab resistant SKBR3 and 
BT474 cells showed an increased intensity of nuclear 
HER4 compared to the sensitive cells. These results 
suggest that HER4 cleavage and nuclear translocation 
occurs during trastuzumab treatment and resistance. 
Depending on the antibodies used and in different 
cell lines (Figure 1B and 1C), we also observed the 
appearance of multiple HER4 bands at 180kDa, 120kDa, 
110 kDa and 80 kDa. To our knowledge, no study has 
reported HER4 variants at 110 and 120 kDa. However, 
these bands were confirmed to be specific to be HER4 
by the siRNA experiments (Figure 3B). From the recent 
publications, other HER receptors were also reported to 
have multiple variants, including HER2 at 185, 150, 110 
and 95 kDa of molecular weight [34, 35] and multiple 
HER3 variants in Schwann cell model [36]. We therefore 
suggest that a future study could be carried out to 
characterize HER4 variants at 110 and 120 kDa to assess 
whether they could represent different HER4 isoforms or 
alternative cleaved fragments. 
Although HER4 has been shown to have an anti-
proliferative activity in breast cancer cells [8-10], we 
showed that HER4 silencing decreased cell viability 
and enhanced trastuzumab effect as well as reversed its 
resistance in HER2 positive breast cancer cells. Our study 
suggested that during trastuzumab treatment, HER4 may 
mediate trastuzumab resistance and reduces its inhibitory 
effect. This seems to contradict other studies [20, 21]. 
However, the controversial effect of HER4 may be 
related to its cellular localisation. HER4 has been shown 
to translocate to the nucleus following its cleavage and 
interact with different transcription factors [32, 37-41]. 
Since trastuzumab induces the release of endogenous 
heregulin [23] and this could induce γ-secretase-mediated 
HER4 cleavage and nuclear localisation [26], we utilized 
γ-secretase inhibitor and showed that it decreased m80 
and nuclear HER4 translocation in HER2 positive breast 
cancer cells when combined with trastuzumab. This was 
correlated with an increase in apoptosis and decreased 
cell proliferation, consistent with reports that γ-secretase 
inhibitor could inhibit heregulin-dependent tumour growth 
[26, 42]. Our study provides evidence that HER4 nuclear 
translocation during trastuzumab treatment is due to its 
proteolytic cleavage mediated by γ-secretase. However, 
we could not exclude that the growth inhibition by 
γ-secretase inhibitor could also be due to its effect on other 
signaling pathways, e.g. Notch or E-cadherin [43, 44]. 
There has been a recent study investigating the 
combination effect of a ganmma-secretase inhibitor in 
combination with docetaxel chemotherapy in breast 
tumorgraft models and in patients with advanced breast 
cancer [44]. The combination of both drugs resulted in 
a preliminary evidence of efficacy in patients (11 partial 
response out of 24 evaluable patients). However, this 
study used gamma-secretase inhibitor to inhibit Notch 
signaling and stem cell renewal but not HER4 cleavage. 
To our knowledge, we are not aware of any study that 
combines trastuzumab with gamma-secretase inhibitor 
to target HER4 cleavage and nuclear localization in 
HER2 positive breast cancer. It is hoped that our study 
may generate interest in targeting HER4 cleavage using 
gamma-secretase inhibitor in HER2 positive breast cancer 
and possibly other cancers.
To assess whether HER4 cleavage and nuclear 
translocation during trastuzumab is due to its tyrosine 
kinase activity, we utilized neratinib, which is an 
irreversible panHER inhibitor that has an effect against 
EGFR, HER2 and HER4 tyrosine kinase activity [45, 
46]. We showed that whereas trastuzumab increased m80 
and HER4 nuclear translocation, neratinib could prevent 
the induction of m80 and HER4 nuclear translocation 
induced by trastuzumab. This highlights the importance 
in understanding the molecular mechanisms of actions 
and resistance between different anti-HER2 therapies. The 
different effects of neratinib and trastuzumab on HER4 
could be one of the reasons why their combination was 
more effective than either drug alone in preclinical models 
[28].
The prognostic value of HER4 expression in 
relation to breast cancer survival has been controversial 
and could be attributed to different HER4 isoforms and 
its localization [11, 13, 17, 47-49]. Four different HER4 
mRNA spliced isoforms known as JM-a/CYT1, JM-a/
CYT2, JM-b/CYT1 and JM-b/CYT2 have been reported, 
which are derived from the alternative HER4 mRNA 
splicing [30, 50, 51]. In contrast to JM-b variant, the JM-a 
region consists of Adam-17 (TACE) cleavage site that 
allows initial process of HER4 proteolytic cleavage to 
produce the extracellular domain (ECD) and intracellular 
domain (ICD) [25, 29, 52]. This is followed by further 
cleavage of HER4 intracellular domain by the γ-secretase 
at the transmembrane domain, resulting in the nuclear 
translocation of HER4 [26]. 
A recent study of HER4 isoform expression in breast 
cancer demonstrated a correlation between JM-a isoforms 
(CYT1 and CYT2) with longer patients’ survival [12]. In 
addition, studies have shown that cytoplasmic HER4 is 
linked with improved survival of breast cancer patients 
[12, 47]. In our cohort study, we also demonstrated a 
similar pattern that high level of cytoplasmic HER4 had a 
better prognosis in HER2 positive breast cancer patients. 
However, positive nuclear HER4 was correlated with 
poorer outcomes in HER2 positive breast cancer patients, 
which is in agreement with Juntilla’ study [17]. These 
suggested that the different reports of HER4 on breast 
cancer survival might be due to failure to look at clinical 
significance of HER4 localisation in these patients. 
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HER4 expression has been reported to be associated 
with increased sensitivity to trastuzumab in patients with 
metastatic HER2 positive breast cancer [21]. Although 
HER2 and HER4 dimerization appeared to be oncogenic 
[53] , a recent study showed that patients with HER2/
HER4 co-over-expression had a better outcome after neo-
adjuvant trastuzumab therapy and adjuvant trastuzumab 
therapy [20]. However, these studies did not directly assess 
HER4 expression in pre and post-trastuzumab treatment 
samples or assess the relation of nuclear HER4 to the 
response to trastuzumab monotherapy and prognosis of 
patients. Although we only had a small number of patients 
in our study, we have demonstrated that trastuzumab 
induced nuclear HER4 upregulation and that nuclear 
HER4 correlated with poorer trastuzumab response as 
well as shorter survival in HER2 positive patients. It will 
be important to further assess the significance of HER2/
HER4 dimerization in relation to trastuzumab treatment 
and prognosis of HER2 positive breast cancer patients 
using validated HER dimerization assays [54].
In summary, this study provides a first report on 
the effect of trastuzumab treatment in HER4 cleavage 
and its nuclear translocation in HER2 positive breast 
cancer. Downregulation of HER4 and strategies to inhibit 
HER4 cleavage and nuclear translocation (by neratinib 
and γ-secretase inhibitor) enhances trastuzumab response 
and reverses its resistance. Furthermore, we showed that 
nuclear HER4 is an adverse prognostic factor and may 
predict poorer trastuzumab response in HER2 positive 
breast cancer. Further validation is required in large 
independent randomized trial to further determine the 
prognostic and predictive role of HER4 in relation to anti-
HER2 treatment in breast cancer patients. 
MATERIALS AND METHODS
Cells culture
MCF-7, BT474 and SKBR3 cell lines were provided 
by cell services lab at Cancer Research UK (Lincoln’s 
Inn Fields laboratory), which has a stringent quality 
control in cell authenticity and has incorporated short-
tandem repeat (STR) profiling for cell line validation. 
Trastuzumab resistant cell lines were generated as 
previously reported [22, 23, 28]. The MCF7, SKBR3, 
and trastuzumab-resistant SKBR3 cell lines were grown 
in DMEM containing 10% FCS and 10% FBS and with 
100 IU/ml Penicillin, 100 mg/ml Streptomycin (PS). 
The BT474 and trastuzumab-resistant BT474 cell lines 
were maintained in RPMI 1640 containing 10% FCS and 
the same concentration of PS. All cells were grown in a 
humidified incubator at 37°C with 5% CO2. Routinely, the 
cells were sub-cultured once a week and the medium was 
changed for three times per week.
HER4 transient transfection
The cells were transfected with specific interfering 
RNAs for HER4 (Qiagen) followed by trastuzumab 
treatment. The transfection reagent in a final volume of 
2 ml/well were prepared an hour before being added onto 
the cells, which comprising the final volume of 20nM 
HER4 siRNA, the Oligofectamine and the Optimem 
serum-free medium. HER4 expression was determined 
at 72-hour post transfection in both protein and mRNA 
levels. To determine the siRNA HER4 efficiency, scramble 
siRNA (All Star Negative siRNA) was used as a control. 
Analysis of HER4 expression
Western blotting and RT-PCR were performed to 
demonstrate the expression of HER4 protein and mRNA. 
Protein lysates preparation and western blot procedure 
were done according to a standard protocol described 
previously [23]. For western blot, the antibodies against 
c-terminus HER4 (Santa Cruz), c-terminus HER4 
(Neomarkers), phospho-HER4 (Santa Cruz, CA) were 
used. 
Total RNA was harvested from the cell lines with 
Total RNeasy Mini Kit (Qiagen). Total RNA (10 ng) 
was reverse transcribed using the iScript DNA synthesis 
kit, with a melting temperature of 62°C. Quantitative 
RT-PCR assays were performed using standard SYBR-
Green protocol. The following primers were used: HER4, 
forward 5’-TGT GAG AAG ATG GAA GAT GGC-3’, 
reverse 5’-GTT GTG GTA AAG TGG AAT GGC-3’, 
β-actin, forward 5’-GGCGGCACCACCATGTACCCT-3’, 
reverse 5’-AGGGGCCGGACTCGTCATACT-3’. The 
exponential route of CT value was converted into a linear 
form using the 2 –ΔΔCT-relative calculation methods. The 
β-actin was used as the relative control.
Cellular fractionation 
The NE-PER Nuclear and Cytoplasmic Extraction 
kit (Thermo Scientific) was used to obtain cytoplasmic 
and nuclear extracts from the experimental cell lines, 
according to manufacturer’s protocol. Both of the 
cytoplasmic and nuclear extracts were then prepared as 
loading samples for western blot analysis of HER4.
Confocal microscopy 
The immunofluorescence staining for HER4 was 
performed to assess HER4 localisation in relation to 
trastuzumab treatment and resistance. Approximately 
10,000 of cells were seeded onto coverslips in 24-wells 
plate, a day before cell treatment. After treatment, the 
medium containing drugs were discarded and the cells 
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were rinsed with PBS twice. The cells were incubated 
with fixation reagents; 4 % PFA, Triton-X and Natrium 
Borohydrate, before blocking with 3% BSA. HER4 
primary antibody was incubated for 3 hours and a 
subsequent incubation with Alexa-546 conjugated 
secondary antibody (rabbit) for 1 hour. The coverslips 
holding the treated cells was than mounted onto a 
microscope slide using the DAPI Fluoromount-G. The 
slides were visualized using the confocal microscopy.
Cell count experiments
Prior to drug treatment or siRNA transfection, 
approximately 10,000 cells were plated in 24-wells 
plate a day before. The cells were then treated with the 
indicated drug(s) or conditions for 3 or 6 days. On the 
day of experiment, the treated cells were washed in PBS 
and harvested with trypsin before cell counting using the 
Coultier counter.
FACS analysis
To assess apoptosis, the cells were stained with 5 μl 
annexin-V-fluorescein isothiocyanate (FITC) and 5 μl of 
propidium iodide (PI). The analysis was run using a flow 
cytometry detector, FACS Calibur (Becton Dickinson). 
The apoptotic cells were analysed at the early stage 
(annexin-V-positive, PI-negative) and the late apoptotic 
stage (annexin-V-positive, PI-positive).
Xenograft studies
The animal experiments have been described in 
previous publications for trastuzumab treatment [24] or 
trastuzumab with neratinib treatment [28].
Human tissue samples
Tissue microarrays (TMA) of HER2 positive breast 
cancer patients were obtained from Oxford Radcliffe 
Biobank. The use of TMAs complies with the Human 
Tissue Act 2004 of UK. Patients’ characteristics and 
histology including age, sex, tumour grade, menopausal 
states, lymph node(s) and ER status as well as patient 
deaths and recurrences were obtained from the medical 
records. 
A set of formalin-fixed paraffin embedded 
tissues was obtained from a clinical trial conducted at 
UOM Patologia Mammaria-Az. Instituti Ospitalieri 
di Cremona. This study was approved by local ethical 
approval (Protocol CE-21392/2012). This study included 
consecutive cases of HER2 positive breast cancer patients 
that underwent trastuzumab window study followed by 
neoadjuvant chemotherapy and trastuzumab treatment, 
which was performed from April 2010 to December 2012. 
Patients’ clinical information was obtained from accessible 
medical records. 
HER4 immunostaining
The IHC technique was performed to assess HER4 
expression in xenograft tumours and patients’ tumours. 
HER4 expression level was scored semiquantitatively 
using the immunoreactive score (IRS). The final IRS 
score was determined by multiplying the intensity score 
(3, strong; 2, moderate; 1, mild; and 0, no staining), with 
the scoring of the percentage of positive cells (4, >80%; 3, 
51–80%; 2, 10–50%; 1, <10%; 0, 0%),  giving the scoring 
between 0 (no staining) and 12 (maximum score). HER4 
staining was catagorized into negative cytoplasmic HER4 
(IRS <6) or positive cytoplasmic HER4 (IRS≥6); negative 
nuclear HER4 (IRS=0) or positive nuclear HER4 (IRS≥1) 
staining.
Statistical Analysis
The data analysis was done using the GraphPad 
Prism 6 for MAC OS X. For in vitro experiments, 
statistical analyses were performed using t-Test for a 
comparison between two groups and one-way ANOVA 
with Bonferonni’s multiple comparison test for a 
comparison among multiple groups. Data were expressed 
as means ± SD. In in vivo models, the Mann-Whitney 
test was used to compare the medians of HER4 protein 
level between two groups while the Kruskal Wallis with 
Dunn’s multiple comparison test was applied on the 
analysis involving more than two groups. The Kaplan-
Meier survival curves analysis and the multivariate Cox 
proportional hazards modeling were carried out in R 
statistical environment (v.2.14.1) (R package: survival 
v2.36-14), to correlate HER4 scorings with disease-free 
and overall survivals. In addition, the correlation of HER4 
scorings with the other clinical parameters was assessed 
using Fisher’s Exact test. For all statistical analysis, P 
values of < 0.05, <0.01 and <0.001 were considered as 
statistically significant and were marked as *, ** and *** 
respectively. 
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